Department of Gastroenterology, The Shengjing Hospital of China Medical University, Shenyang 110022, Liaoning Province, China.
World J Gastroenterol. 2024 Sep 28;30(36):4025-4030. doi: 10.3748/wjg.v30.i36.4025.
Inflammatory bowel disease (IBD) is a chronic gastrointestinal inflammatory disease. With the emergence of biologics and other therapeutic methods, two biologics or one biologic combined with a novel small-molecule drug has been proposed in recent years to treat IBD. Although treatment strategies for IBD are being optimized, their efficacy and risks still warrant further consideration. This editorial explores the current risks associated with dual-targeted treatment for IBD and the great potential that fecal microbiota transplantation (FMT) may have for use in combination therapy for IBD. We are focused on addressing refractory IBD or biologically resistant IBD based on currently available dual-targeted treatment by incorporating FMT as part of this dual-targeted treatment. In this new therapy regimen, FMT represents a promising combination therapy.
炎症性肠病（IBD）是一种慢性胃肠道炎症性疾病。随着生物制剂和其他治疗方法的出现，近年来提出了使用两种生物制剂或一种生物制剂联合新型小分子药物来治疗 IBD。尽管正在优化 IBD 的治疗策略，但它们的疗效和风险仍需要进一步考虑。本社论探讨了目前与 IBD 的双靶向治疗相关的风险，以及粪便微生物群移植（FMT）在 IBD 联合治疗中的潜在巨大应用价值。我们专注于根据目前可用的双靶向治疗，将 FMT 纳入该双靶向治疗中，来解决难治性 IBD 或生物耐药性 IBD。在这种新的治疗方案中，FMT 代表了一种有前途的联合治疗。
